Retrospective, observational study evaluating role of Polyspecific Organ Cation Transporter 1 mRNA expression in hepatocellular carcinoma patients as a biomarker in systemic treatment with sorafenib.
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 11 Nov 2016 New trial record